April 13, 2010 (FinancialWire) — Nabi Biopharmaceuticals (NASDAQ: NABI) said that the European Patent Office upheld the company's opposition to European Patent No. 1,329,226 (Hapten Carrier Conjugates for Use in Drug Abuse Therapy) requesting revocation of this patent. The EPO revoked the patent in its entirety.

The patent was filed by Xenova Research Ltd., which was subsequently acquired by Celtic Pharma in 2005. On February 15, 2008, Nabi, along with four other parties, filed an opposition against this patent, requesting revocation of the Xenova patent in its entirety.

As a result of this EPO decision, Celtic Pharma has lost its exclusive patent rights to nicotine conjugate vaccine technology in Europe. Xenova Research Ltd., still named as the proprietor of the patent, has the opportunity to file a Notice of Appeal within a period of two months from the March 29, 2010 date of the EPO written decision.

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[frlylrf] [ltgnltgn] [biomedphrm] [erpnpre]